Mar 8 2010
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced that the Japanese Patent Office
has issued a patent for its novel anti-cancer compound, Archexin®.
“The Japanese patent award is another step forward in the development of
one of our lead clinical drug candidates, Archexin”
“The Japanese patent award is another step forward in the development of
one of our lead clinical drug candidates, Archexin,” said Dr. Chang Ahn,
Rexahn's Chairman and Chief Executive Officer. “In addition to
strengthening our intellectual property portfolio, we are pleased with
the progress of Archexin’s ongoing Phase II clinical trial for the
treatment of pancreatic cancer. Patient enrollment continues at multiple
sites in the US and abroad and we expect to have preliminary results in
the fourth quarter of 2010.”
Archexin is a first in class, potent inhibitor of Akt protein kinase in
the treatment of cancer. Akt regulates signal processes of cell
proliferation and survival, angiogenesis, and drug resistance in cancer.
Archexin is being developed to treat solid tumors and has FDA Orphan
drug designation for RCC, pancreatic, stomach, glioblastoma, and ovarian
cancers. Archexin is in Phase II clinical development for pancreatic
cancer as lead indication.
About Rexahn Pharmaceuticals, Inc.
MRI-guided SBRT reduces side effects in prostate cancer treatment